Sanara MedTech (SMTI) Projected to Post Quarterly Earnings on Monday

Sanara MedTech (NASDAQ:SMTIGet Free Report) is anticipated to announce its earnings results before the market opens on Monday, March 24th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $22.75 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Sanara MedTech Stock Performance

Shares of SMTI stock opened at $32.39 on Monday. The company has a quick ratio of 2.02, a current ratio of 2.23 and a debt-to-equity ratio of 0.76. The business has a 50 day moving average of $34.26 and a two-hundred day moving average of $33.88. Sanara MedTech has a 52 week low of $26.00 and a 52 week high of $39.08. The company has a market cap of $283.12 million, a P/E ratio of -32.72 and a beta of 1.37.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SMTI. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $44.00 price target on shares of Sanara MedTech in a report on Wednesday, January 22nd. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Sanara MedTech in a report on Thursday, January 23rd.

View Our Latest Research Report on Sanara MedTech

About Sanara MedTech

(Get Free Report)

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.

Featured Stories

Earnings History for Sanara MedTech (NASDAQ:SMTI)

Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.